PHILADELPHIA , April 29, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE) , a medical device company developing its Symphony ® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it has mailed the following letter to stockholders in connection with the proxy contest that has been threatened at Echo's 2014 Annual Meeting of Stockholders by a dissident stockholder group led by Platinum Management (NY) LLC:
April 29, 2014 Dear Fellow Stockholder: Echo Therapeutics, Inc. has recently filed revised proxy materials with the Securities and Exchange Commission (SEC) in connection with Echo's 2014 Annual Meeting of Stockholders, including a preliminary form of a revised proxy statement and a preliminary form of a revised WHITE proxy card.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.